Stock Market Reviews

Read and share opinions on COCP (Cocrystal Pharma, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
  Nov 14, 2025
• Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
  Oct 30, 2025
• Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
  Oct 27, 2025
• Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
  Oct 2, 2025
• COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…
  Sep 17, 2025
• Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  Sep 15, 2025
• Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  Sep 12, 2025
• Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
  Sep 12, 2025
• Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
  Sep 8, 2025
• Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
  Sep 3, 2025
• COCP: Norovirus Challenge Study to Initiate in 4Q25…
  Aug 19, 2025
• Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
  Aug 14, 2025
• Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
  Aug 5, 2025
• Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
  Jul 10, 2025
• Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
  Jun 5, 2025
• Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
  May 29, 2025
• Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
  May 28, 2025
• COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25…
  May 27, 2025